Someone who search "story stock" and "baltbear" would find the evidence that you are approaching something.
There is a "story" here. That's what there is. Nothing else, except a specialist's chew toy.
But yeah....buying NFLX late in 2012, along with the gut checks, double downs and trading into accumulation was an excellent case of understanding the story of a stock--which is different than a story stock.
Back at the time I told peopke here to look closely at NOK--where my average client ended up with 4k shares at --0-- basis, AND better than 20% APR on risk capital.
OOOOOO.. An actual investing question, and not whywhywhy divs, buybbacks, rat's rumpos and financiual games.
Easy guess---when BNSF's insurer drops it. Probably not before.
The idea of having to listen to that goniff for 24 minutes is wayyy too much.
Is there a transcription somewhere, so I can print it out--so that I can roll it into a cone and have a barf bag if I need it?
since clone has admitted in the past to trading in and out, just like the cronies do, and ips and msft run in a pack with him--they are likely all drones for some bucket shop tied to insiders.
Read the CIRM proposal. It's based on GERN's report of "no harmful side effects--and no benefits."
CArtilege and bone have nothing at all to do with nerve cells.
Congratulations on demonstrating once again what a compleat idiot you think readers here are.
Yup. Why? Becuase the initial dose did nothing. Since the nothing included "nothing negative" its getting doubled. As well as the injection site getting moved, on the off chance that might make a difference.
Now: subtract the amount of cash on hand or committed that MUST be spent on this exercise, and how much is left? Maybe enoughto put off the next round of dilution til q3 of 15.
Excellent but meaningless question--until the range of factors is named.
Example? What correction would,be required to account for George Washington being in the top 100 or so of wealthy Americans, but not have "indoor plumbing" or a VCR?
"Dollars"-- like anything else, are never more than nominal.
On the other hand--as jad often seems to note--quite often something that seems out of line when viewed with an older model does point to errors in newer methodologies. And that then becomes the bet that creates the 2 sides on any trade.
NOK? More/less same way as always...tonnes of dd. Along with a version of law of a baltbear vikinged from WB and Peter Lynch--if you don;t understand it, don;t own it.
Getting clients into BAC at at net basis of ~2 was the same kind of thing. Along with "bad call" of "chasing yield" and writing covered 10s, instead of waiting for 15---since my calculations showed no way for BAC to hit 15 til about 2016. That got smacked down by "big banks" skull-ph***ing the Feds.
I woof at HC for continually inventing single point scenarios left over from 1972 to no real end other than getting the chance to say "shameful" about whoever / whatever played the game better than he does.
Typical of dropouts everywhere--and he is, by his own admission, a '92 dropout.
I didn't dropout until succession plan satisfied me, AND I had to admit being too slow mentally to play FB at all.
You and I both understand that much of this stuff bases in a priori--like 22.5 or "inverse of the long". My pov has always been that all those axioms are nonsense--but when they are widely adopted they move the tape.
HC pretends that whatever he got taught in 1970 is "natural law." I got taught that the only "natural law" was what took out Ira Haupt, letting WB make his bones on American Express.
Thumbs up. Good to see you about. I'm enjoying your comments in re methodology on another thread.
the yelling is me attempting to explain to HC how a successful succession plan beats his dancing-girl fueled visions of a welfare state for the likes of him and his.
"I have not found any favorable deals in quite some time." is a lot more true than when/if "bubble." and applies to way more than puts.
Either way, "long period of dead money" seems highly likely--except for carefully dd'd individual stocks and private placements.
He forgot reason #1 to dump an advisor: If he's commission based.
#2. If his fee structure is not utterly transparent.
Somewhere around #4 oughta be if he follows more than one of : Barron's, Forbes, Morning Joe, Maria-baby, Cramer, or..... (additions to this list welcome.)
And from the "no spending" will come "no revenue." Why would Asterias deliver votable shares to retail cannon fodder before the insiders have their cut of the pie, and before it needs another tranche to dilution to be fronted by Cox/Agora et al?
"Under the terms of the settlement and license agreement, the parties will each receive a non-exclusive, worldwide, royalty-free, fully paid-up, license to use certain patents for any internal research and development purpose but only to the extent necessary to allow the licensee to make, use, sell, offer for sale, or import endodermal lineage cells for use with its products and/or product candidates."
That is, it doesn;t matter one dang bit to BTX shareholders that Viacyte filed for anything....until well after a successful phase I,II period, at which point BTX will launch yet another "me, too" product.
So far as Viacyte being a JNJ development corporation---not so much. JNJ is a shareholder, especially when CA taxpayers subsidise it.
" announced today that it completed a private equity financing transaction, providing the Company $10.6 million through the sale of Series C-1 Preferred Stock, together with warrants to purchase stock. The financing, conducted as a rights offering to ViaCyte Series B and C Preferred Stock holders, included the Company's largest existing investors - Johnson & Johnson Development Corporation, Sanderling Ventures and Asset Management Company (Johnson Trust).
This funding serves as a match for a $10.1 million Strategic Partnership Award (SPA) that was approved last October by the California Institute for Regenerative Medicine (CIRM) to support clinical evaluation of VC-01, "
"Sometimes it works." Yeah.. but most of the time is provides exercises in the gamblers' fallacy, known in the industry as the recipe for making retail road kill.
I also see that 33% idea as an example of road kill thinking. Nothing wrong with 75% of BASIS so long as basis is way below present tape.
Nope ---that was 2012.
Currently 2015 is scheduled to be the year when the next major round of dilution happens.
Anyone needing any proof of this only needs to look at how Mikey demanded his options be priced going out...
Mauldin describes himself as a "serial entrepreneur." Having seen his work, I put him in the same class as BTX insiders and cronies ---he works for himself and nobody else.
Excellent. So? What's the cost, and time to completion?/
Otherwise it's just another press release.
Especially without the FDA response.
"allow them to persue this IND." Yup. NOT "file an IND."
Good to see you about.
Next question: how much spending between today and an actual IND?
Coming from what cash on hand not contractually obligated to something else?
And only then onto what is the actual JNJ contract? When does it put $1k positive to BTX?
And from there, back to today's volume and direction of the tape.
Because none of it is "news" to any one in biotech, and none of it has any content to anyone in finance and equities.
Bottom line is that any pro knows that BTX has said nothing since 2008 that will convert to $1k over COG and G&A within 5 years. And as of this week, it's still doing that. Since even "Four more years" is going to double the o/s, or doors close. it can be ignored or shorted at will. It's an MM'c chew toy. No more; no less.